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Abstract 1 
The standard of care treatment for canine lymphoma is multi-agent chemotherapy containing 2 
prednisolone, cyclophosphamide, vincristine and an anthracycline such as doxorubicin (CHOP) 3 
or epirubicin (CEOP).  Lomustine, vincristine, procarbazine, and prednisone (LOPP) has been 4 
evaluated as a rescue, with encouraging results; however, resistance to vincristine is likely in 5 
patients relapsing on CHOP/CEOP, and this agent may enhance LOPP toxicity without 6 
improving efficacy. The aim of this study was to evaluate responses to a modified LOPP 7 
protocol that does not include vincristine (LPP) and is administered on a 21-day cycle. Medical 8 
records of dogs with high grade multicentric lymphoma from 2012 to 2017 were reviewed. 9 
Dogs with relapsed lymphoma that received LPP as a rescue protocol were enrolled. Response, 10 
time from initiation to discontinuation (TTD) and toxicity of LPP were assessed. Forty-one 11 
dogs were included. Twenty-five dogs (61%) responded to LPP including 12 complete 12 
responses (CR) and 13 partial responses (PR). Responders had a significantly longer TTD (p 13 
<0.001) compared to non-responders with 84 days for CR and 58 days for PR. Neutropenia was 14 
documented in twenty dogs (57%): 12 grade I-II, 8 grade III-IV. Thrombocytopenia was 15 
infrequent (20%): 5 grade I-II, 2 grade III-IV. Twelve dogs developed gastrointestinal toxicity 16 
(30%): 10 grade I-II and 2 grade III.  Nineteen dogs had elevated ALT (59%): 9 grade I-II, 10 17 
grade III-IV. Treatment was discontinued due to toxicity in 8 dogs (19%). The LPP protocol 18 
shows acceptable efficacy and toxicity-profile and minimises in-hospital procedures.  19 
 20 
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 2 
 Introduction 23 
Haematopoietic neoplasia is common in dogs, with canine non-Hodgkin lymphomas (cNHLs) 24 
making up over 80% of all hematopoietic cancer.1,2 Among cNHLs, high grade B-cell 25 
lymphomas prevail and first-line chemotherapy consists of maintenance free CHOP or CEOP-26 
based protocols including prednisolone, vincristine, cyclophosphamide and an anthracycline 27 
such as doxorubicin (CHOP) or epirubicin (CEOP).2–8 High grade T-cell lymphomas are less 28 
common and though response rates and duration are shorter, treatment is similar. 9 The overall 29 
response rate for CHOP/CEOP protocols is between 89-100% and the median ﬁrst remission 30 
duration is 142 to 302 days.2–8 However, median ﬁrst remission duration for T-cell cNHL is 31 
shorter than 5 months, compared to 11 months for B-cell cNHL.2–9   32 
Despite an initial response, most dogs relapse and rescue chemotherapy is used to achieve a 33 
second remission. Rescue strategies are usually less effective than first-line protocols, showing 34 
a wide range of response rates (18-77%) and remission durations (56-238 days). 10–25  35 
 36 
ATP-binding cassette superfamily (ABC) proteins such as P-glycoprotein (P-gp) or multidrug 37 
resistance-associated proteins may be involved in the development of resistance to first-line 38 
chemotherapy. 26–29 ABC protein superfamily proteins should not mediate resistance to 39 
alkylating agents, so their use in a rescue setting is appealing. 30  40 
 41 
In 2002, Rassnick and colleagues evaluated the efficiency and tolerability of a 42 
mechlorethamine, vincristine, procarbazine and prednisolone protocol (MOPP).24 MOPP 43 
demonstrated adequate efficacy (65% response rate) and an acceptable toxicity profile; 44 
however, due to the difficulty in obtaining mechlorethamine, LeBlanc and colleagues replaced 45 
it with carmustine (BOPP) or lomustine (LOPP).19 Both protocols demonstrated good remission 46 
rates (50-52%) but severe adverse effects occurred. Consequently, Fahey and colleagues 47 
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proposed a modified-LOPP protocol (UF-LOPP) with decreased dose intensity.15 The response 48 
rate was similar to the previous study, but fewer adverse effects were recorded.  49 
The inclusion of vincristine in rescue protocols contributes in potentiating dose intensity, but 50 
its role is debatable in patients that have previously failed CHOP-based strategies. Additionally, 51 
vincristine may be the major contributor to gastrointestinal toxicity in LOPP or MOPP.15,19,24 52 
For these reasons, a modified MOPP protocol without vincristine (MPP) was designed 53 
demonstrating moderate efficacy (34% response rate) and a low toxicity profile.22   54 
 55 
The primary aim of this retrospective study was to evaluate efficacy and toxicity of a modified 56 
LOPP rescue protocol combining lomustine, procarbazine and prednisolone (LPP) in canine 57 
relapsed lymphoma. A secondary aim was to identify predictive factors for response and 58 
occurrence of adverse effects.  59 
 60 
Materials and methods 61 
Study population  62 
The computerised clinical database of the University of Liverpool was searched for dogs treated 63 
with LPP protocol January 2012 and July 2017. To be eligible for the study, patients had to 64 
fulfil the following criteria: (1) histological or cytological diagnosis of high grade cNHL 65 
performed by a veterinary board certified veterinary pathologist or clinical pathologist; (2) 66 
multicentric disease (3) lymphoma relapse following previous administration of, at least, one 67 
first line chemotherapy protocol; (4) follow-up measurement of peripheral lymph nodes from 68 
initiation to discontinuation of LPP. Patients with exclusive gastrointestinal involvement were 69 
excluded from the study. Discontinuation of prednisolone during the LPP protocol and absence 70 
of restaging prior to LPP initiation did not result in exclusion. The study was approved by the 71 
University of Liverpool ethics committee (VREC138). 72 
 4 
Medical record review  73 
Data retrieved from the medical records consisted of  sex, age, breed, body weight, lymphoma 74 
stage, sub-stage, immunophenotype, number of previous chemotherapy agents/protocols 75 
received, initial response to first line protocol, number of previous relapses, administration of 76 
L-asparaginase within 14 days prior to LPP initiation, duration from initial diagnosis to LPP 77 
initiation, lomustine/procarbazine/prednisolone dosage, procarbazine dosing schedule, number 78 
of LPP cycles received, results of complete blood count (CBC) and ALT activity, response to 79 
LPP, time from initiation to discontinuation of the LPP protocol (TTD), reason for LPP 80 
discontinuation, overall survival time and cause of death.  81 
 82 
Diagnosis and staging  83 
Dogs were staged at time of the initial diagnosis based on the World Health Organisation 84 
(WHO) five-stage criteria for canine lymphoma.31 Staging investigations included physical 85 
examination, CBC, serum biochemical analysis, lymph node cytology/histology. The following 86 
diagnostic investigations were performed according to clinician’s discretion: 87 
immunohistochemistry, flow-cytometry (lymph node, blood and/or bone marrow), PARR (PCR 88 
for Antigen Receptor Rearrangement), urinalysis, thoracic radiographs, abdominal ultrasound, 89 
splenic, hepatic and bone marrow cytology.  90 
 91 
Treatment protocol  92 
The LPP protocol is summarized in table 1. Doses were calculated to the nearest 5 mg for 93 
lomustine (Medac GmbH, Theaterstr. 6. 22880 Wedel, Germany) and 10 or 25 mg for 94 
procarbazine (Alliance Pharmaceuticals Limited, Chippenham, Wiltshire, SN15 2BB, UK) 95 
based on the availability of smaller capsules (reformulated by Nova Laboratories Ltd, Leicester, 96 
LE18 4YL, UK). Based on the dog’s weight and the available procarbazine capsule size, several 97 
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dosing schedules (daily, every other day, one day off a week, or one day off every three days) 98 
were used to achieve an average target procarbazine dose of 50 mg/m2/day. All dogs received 99 
S-adenosylmethionine and silybin (Denamarin®, Nutramax Laboratories Veterinary Sciences, 100 
Inc., Lancaster, SC 29720) after each lomustine treatment and the duration of this treatment 101 
was established according to clinician discretion.  102 
 103 
Response assessment 104 
Clinical response to treatment was assessed via calliper measurements of peripheral lymph 105 
nodes. Thoracic and/or abdominal imaging was repeated to assess response at clinician’s 106 
discretion. Response to treatment was assessed as follow: a complete response (CR) was 107 
clinically defined as disappearance of all measurable disease; a partial response (PR) was 108 
defined as > 50% but < 100% reduction in measurable disease; a stable disease (SD) was 109 
defined as < 50% reduction for 21 days or < 25% increase in size of all measurable disease with 110 
no appearance of new lesions; progressive disease (PD) was defined as > 25% increase in 111 
measurable disease or appearance of new lesions.15,19,22,24 Transient decreases in measurable 112 
disease that persisted for < 21 days were defined as progressive disease. Thus, dogs were also 113 
divided into responders (CR + PR) and non-responders (SD + PD). Treatment was continued 114 
in patients that had CR or PR. Treatment was discontinued when there was SD, PD, toxicity or 115 
other reasons (financial constraints, euthanasia unrelated with lymphoma). 116 
 117 
Assessment of toxicity 118 
Evidence of toxicity was assessed by evaluation of the medical record, including medical 119 
history obtained from owners and results of physical examination and clinicopathological data. 120 
CBC was recommended prior to LPP initiation, one week after the first lomustine treatment, 121 
one week after each lomustine dose adjustment and prior to each new cycle. ALT activity was 122 
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measured prior to LPP initiation and prior to each new cycle. Toxicity was retrospectively 123 
graded according to criteria established by the Veterinary Co-Operative Oncology Group.32 124 
Neutropenia, thrombocytopenia, increase in ALT activity, vomiting, diarrhoea and anorexia 125 
were evaluated. If baseline ALT activity was high prior to treatment, an elevation in ALT 126 
activity was recorded only if the maximum ALT activity during the LPP protocol was > 1.5-127 
fold ALT activity at baseline. Dose adjustments and treatment delays were made according to 128 
clinician and owner’s discretion, commonly if VCOG grade > II toxicity occurred.  129 
 130 
Statistical analysis  131 
Descriptive statistics were calculated, and data were tested for normal distribution and equal 132 
variance by means of the Shapiro Wilk test and F-test, respectively.  133 
The overall, CR and PR rates were defined as the number of dogs achieving CR/PR, CR and 134 
PR respectively, compared with the total number of dogs treated. The TTD was defined as the 135 
time from the initiation of the LPP protocol until discontinuation due to PD or toxicity. Overall 136 
survival time (OS) was defined as the time from diagnosis to death. Dogs that were in clinical 137 
remission at the end of the data collection or discontinued the LPP protocol because of financial 138 
constraints or lymphoma-unrelated death were censored. TTD and OS were calculated using 139 
the Kaplan-Meier method. As the timing of euthanasia is determined by a combination of 140 
clinical factors, clinician and owner judgement, OS was not an endpoint of this study. 141 
The following predictor variables were used for statistical analysis : weight, age, sex, stage, 142 
sub-stage, immunophenotype, response to first line chemotherapy protocol (CR vs others), 143 
duration of first remission, time from the diagnosis to LPP initiation, number of previous 144 
protocols/chemotherapy agents and relapses, relapse during first-line protocol, use of L-145 
asparaginase within 14 days prior to LPP initiation, lomustine/procarbazine/prednisolone dose 146 
(in mg/m2 body surface area and mg/kg for lomustine; in mg/m2/day and mg/kg/day for 147 
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prednisolone and procarbazine), procarbazine dosing schedule, prednisolone use, occurrence of 148 
grade III-IV neutropenia, ALT increase and gastrointestinal toxicity. For the purpose of 149 
statistical analysis, procarbazine dosing schedule was divided as: continuous procarbazine (C-150 
PCB: daily administration or one day off a week) and “pulsatile” procarbazine (P-PCB: every 151 
other day administration or one day off every three days). The daily average procarbazine doses 152 
(mg/m2/day and mg/kg/day) was calculated from the total cumulative intended dose divided by 153 
the 14 intended days of administration. The influence of these variables on response (CR/PR vs 154 
SD/PD), occurrence of gastrointestinal toxicity (including anorexia, vomiting and diarrhoea), 155 
grade III-IV neutropenia and grade III-IV ALT increase was analysed. For univariable analysis, 156 
Fisher exact test, t-test and Wilcoxon rank sum test were used to analyse the influence of 157 
categorical, continuous normal and continuous non-normal variables on the type of response, 158 
respectively. Binomial logistical regression was used for multivariable analysis. 159 
Log rank test was used to compare TTD according to previously mentioned categorical 160 
predictor variables and Cox proportional-hazard regression was used for continuous variables 161 
and multivariable analysis.  162 
Variables significant at 0.2 on bivariate analyses were entered into a multivariable model 163 
followed by a backwards stepwise protocol. All analyses were two-sided, and p<0.05 was 164 
considered to be significant. All statistical calculations were carried out with the R statistical 165 
software version 3.2.0 using the “survival” package. 33,34  166 
 167 
 168 
Results 169 
Patients  170 
Forty-one client-owned dogs met the inclusion criteria. The median age was 7.9 years (range 171 
2.6 –14.7 years). The median weight was 28.8 kg (range 6.5 - 76.3 kg). There were 5 intact 172 
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males (M), 20 neutered males (MN), 1 intact female (F) and 15 neutered females (FN). There 173 
were 8 mixed-breed dogs. Boxer (n=4), border collie (n=4), beagle (n=2), Rack Russel terrier 174 
(n=2), English springer spaniel (n=2) were the most commonly affected breeds, with 19 other 175 
breeds represented by one dog each.  176 
 177 
High grade/large cell lymphoma was diagnosed through cytology in all patients and in 17.1% 178 
(n=7) this was also confirmed via histopathology. All dogs had at least stage III multicentric 179 
lymphoma at presentation, with 8 dogs suspected of having stage V lymphoma based on 180 
confirmed bone marrow involvement (n=1), marked CD34- lymphocytosis (n=3), bladder 181 
involvement (n=1), lymphomatous pleural effusion (n=1), suspected lung involvement (n=1) 182 
and suspected central nervous system involvement (n=1). Twenty-three (56%) and 18 (44%) 183 
were sub-stage a and b, respectively. Immunophenotype was evaluated in 25 dogs (61%). Of 184 
these, 19 (76%) had B-cell and six (24%) had T-cell lymphoma. The overall median survival 185 
time was 367 days (range 64-913 days).  186 
 187 
Previous treatments    188 
Thirty-seven dogs (90%) had CEOP as a first line chemotherapy protocol and COP was used 189 
in 4 dogs. Thirty-three (80%) achieved complete clinical remission and 8 (20%) achieved partial 190 
remission. The median duration of first complete remission was 153 days (range 7-976).  191 
At relapse, cytological confirmation of disease progression was obtained in 13 dogs (31.7%). 192 
The median number of relapses prior to LPP was 2 (range 1-3). The median number of previous 193 
chemotherapy protocols was 2 (range 1-4) and the number of previous chemotherapy agents 194 
was 5 (range 4-9). The median duration from the date of diagnosis to the date starting LPP was 195 
202 days (range 33-397). L-asparaginase was used within 2 weeks prior to LPP in 8 cases 196 
(19.5%). None of the dog that received L-asparaginase were in CR at the initiation of the LPP 197 
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protocol. Seven dogs received lomustine prior to LPP initiation: one dog, 2 dogs and 4 dogs 198 
received 3, 2 and 1 previous lomustine administration, respectively. All dogs were receiving an 199 
ongoing chemotherapy treatment at the time of relapse and the treatment free period prior to 200 
LPP was short (median 14 days, range 5-35 days). 201 
 202 
LPP protocol  203 
The median starting doses of lomustine, procarbazine and prednisolone were 58 mg/m2 (range 204 
47-68 mg/m2), 48 mg/m2/day (range 34-66 mg/m2/day) and 28 mg/m2/day (range 0-33 205 
mg/m2/day), respectively. In mg/kg, the median starting dose of lomustine, procarbazine and 206 
prednisolone was 1.98 mg/kg (range 1.34-2.99 mg/kg), 1.75mg/kg/day (range 0.92-2.55 207 
mg/kg/day) and 0.86 mg/kg/day (range 0-1.5 mg/kg/day), respectively. Prednisolone was not 208 
administered in 7 cases (17.1%). Thirty-two dogs (78%) received a continuous procarbazine 209 
dosing schedule (C-PCB group): 28 dogs had daily procarbazine and 4 had daily procarbazine 210 
with one day off per week. Nine dogs (22%) received a “pulsatile” procarbazine dosing 211 
schedule (P-PCB): 7 had every other day administration and 2 had one day off treatment every 212 
three days. The average daily procarbazine dose in mg/m2/day was not statistically different 213 
between the two procarbazine dosing schedule groups (p=0.26) whereas in mg/kg/day, dogs in 214 
the P-PCB group (median 2.08 mg/kg/day, range 1.55-2.48 mg/kg/day) received a significantly 215 
(p=0.03) higher dose compared to C-PCB (1.54 mg/kg/day, range 0.92-2.55 mg/kg/day). 216 
Similarly, the lomustine dose in mg/m2 was not significantly different between dogs in P-PCB 217 
and C-PCB whereas when expressed in mg/kg, dogs in P-PCB received a significantly higher 218 
lomustine dose (p<0.001, P-PCB: median 2.5 mg/kg; range 2.13-2.85 mg/kg vs C-PCB median 219 
1.8 mg/kg; range 1.34-2.99). The body weight of dogs in the P-PCB group was significantly 220 
(p<0.001) lower (median=11 kg, range: 6.5-17.7 kg) than dogs receiving C-PCB (median: 29.7 221 
kg, range 8.3-76.3 kg).  222 
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 223 
Of the 41 dogs treated, 12 dogs (29%) achieved CR, 13 (32%) achieved PR, and 16 (39%) had 224 
SD or PD, for an overall response rate of 61%. CR was achieved following the first cycle in 11 225 
dogs and one dog was in PR following the first cycle and achieved CR only following the 226 
second cycle. Two dogs had repeated imaging to assess response during the protocol. One dog 227 
had peripheral lymphadenopathy and restaging prior to LPP initiation revealed a bladder mass 228 
with cytology consistent with large cell lymphoma. Therefore, focal bladder ultrasound was 229 
performed prior to each new LPP cycle. A significant reduction (>50%) of the bladder mass 230 
size was initially documented following LPP initiation although a mild thickening of the 231 
bladder wall persisted. This dog was thus considered a partial responder. LPP was discontinued 232 
following grade IV ALT increase though neither peripheral lymphadenopathy nor bladder mass 233 
enlargement was documented. Another dog had mediastinal lymph nodes involvement and 234 
thoracic ultrasound was repeated prior to each new LPP cycle. Partial response was documented 235 
following the first LPP cycle but the size of the mediastinal lymph nodes increased by more 236 
than 50% (consistent with PD) after the second cycle and LPP was discontinued.  237 
 238 
On univariable analysis, CR on first-line protocol (p=0.02) and gastrointestinal toxicity 239 
(p<0.01) were significantly associated with overall response (CR/PR vs SD/PD). Other factors 240 
were not significant in univariable analysis (data not shown). Average daily procarbazine dose 241 
in mg/kg/day (p=0.06), lomustine dose in mg/kg (p=0.17), weight (p=0.07), VCOG grade III-242 
IV ALT increase (p=0.15) were also included in multivariable analysis. On multivariable 243 
analysis, CR on first remission (p=0.01, OR 28.53 95% CI 2.14-379) and average daily 244 
procarbazine dose in mg/kg/day (p= 95% OR 10.0 CI 1.18-85) were significantly associated 245 
with response (CR/PR vs SD/PD). Among the 33 dogs who achieved CR on first line protocol, 246 
23 (70%) responded to LPP. For the 8 dogs that did not achieve CR on first line protocol, only 247 
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2 dogs (25%) responded to LPP. The median average daily procarbazine dose for responders 248 
was 1.8 mg/kg/day whereas it was 1.47 mg/kg/day for non-responders. Eleven of twelve dogs 249 
(92%) with gastrointestinal toxicity responded to LPP whereas response was identified in 15 250 
dogs out of 29 (48%) without gastrointestinal toxicity. Although the association between 251 
procarbazine dosing schedule and response was not statistically significant (p=024), the overall 252 
response rate for dogs in the P-PCB group was 77% whereas it was only 56% for dogs in the 253 
C-PCB group.  254 
 255 
The protocol was discontinued because of disease progression or toxicity in 30 (73%) and 8 256 
dogs (19.5%) respectively. In 1 dog, LPP was discontinued because of financial constraints and 257 
1 dog was euthanised due to deterioration of osteoarthritis. One dog was still in CR at the time 258 
of data analysis.  259 
 260 
The median TTD was 34 days (range 12-167 days) and the median number of LPP cycle was 261 
one (range 1-7). On univariable analysis, neutered female (p=0.042), dogs without recent L-262 
asparaginase (p<0.01), complete and partial responders (p<0.001), dogs receiving P-PCB 263 
(p=0.05) and dogs with grade III-IV ALT increase (p=0.05) had significantly increased TTD 264 
(Table 2). Other factors were not significant in univariable analysis (data not shown). On 265 
multivariable analysis, only the achievement of partial (p<0.001, HR 0.1, 95% CI 0.03-0.34 for 266 
TTD) or complete response (p<0.001, HR 0.02, 95% CI 0.006-0.11 for TTD) was significantly 267 
associated with TTD. The median TTD for complete responders was 84 days (range 23-167 268 
days), 58 days (range 19-75 days) for partial responders and 21 days (range 19-22 days) for 269 
SD/PD (Figure 1). 270 
  271 
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After failing LPP, 28 dogs (68%) went on to receive additional rescue protocols, with DMAC 272 
(dexamethasone, melphalan, actinomycin D, cytosine arabinoside) and LMP (chlorambucil, 273 
methotrexate and prednisolone) being the most common. The median survival time following 274 
LPP discontinuation was 25 days (range 0-676).  275 
 276 
 277 
Toxicity  278 
Gastrointestinal toxicity occurred after at least one treatment in 12 dogs (29 %). Among them, 279 
7 (58%), 3 (25%), and 2 (17%) dogs had VCOG grade I, II and III gastrointestinal toxicity 280 
respectively (Table 3). Diarrhoea was the most common gastrointestinal adverse effect (n=10).  281 
Six dogs (15%) were hospitalised due to gastrointestinal toxicity and recovered rapidly with 282 
supportive management. Several factors were significantly associated with the occurrence of 283 
gastrointestinal toxicity on univariable analysis: weight (p=0.04), CR on first-line protocol 284 
(0.04), response to LPP (<0.01) and the average daily procarbazine dose in mg/kg/day 285 
(p<0.001). On multivariable analysis, only the average daily procarbazine dose in mg/kg/day 286 
was significant (p<0.01). The median dose for dogs with or without gastrointestinal toxicity 287 
was 2.14 mg/kg/day (range 1.34-2.55 mg/kg/day) and 1.57 (range 0.92-2.48 mg/kg/day), 288 
respectively. The weight for dogs with gastrointestinal toxicity (median 19.45 kg; range 9.75-289 
41.7 kg) was significantly lower than those without toxicity (median 29.4 kg, range 6.5-76.3 290 
kg). Interestingly, 50% of the dogs weighing less than 14kg had gastrointestinal toxicity 291 
whereas only 23% of the dogs weighing more than 14kg experienced gastrointestinal toxicity.  292 
 293 
At baseline, all dogs had a CBC performed. None of the dogs were neutropenic, 3 had VCOG 294 
grade I thrombocytopenia and 6 were anaemic (4 grade I, 1 grade II). CBC was performed one 295 
week following the first lomustine dose for 35 dogs (85%) and before every new cycle for all 296 
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dogs. Neutropenia was documented in 20 dogs (57%) 7-10 days following lomustine 297 
administration. Thrombocytopenia was documented in 7 dogs (20%). Eight dogs (23%) and 2 298 
dogs (5%) had VCOG grade III-IV neutropenia or thrombocytopenia, respectively (Table 2). 299 
None of the dogs with grade III-IV neutropenia were hospitalised. On univariable analysis, 300 
weight (p=0.03) and procarbazine dosing schedule (p-0.03) were associated with the occurrence 301 
of grade III-IV neutropenia. Due to the low number of grade III-IV neutropenia, multivariable 302 
analysis was not performed. The weight of dogs with high-grade neutropenia was significantly 303 
lower (median 17 kg, range 9.75-28.9 kg) than for those without high-grade neutropenia 304 
(median 29.4 kg, range 6.5-76.3 kg). Four of 9 dogs (44%) receiving P-PCB had high-grade 305 
neutropenia whereas only 12% of dogs receiving C-PCB had high-grade neutropenia.  306 
 307 
Serum ALT activity was available in 39 dogs at baseline and among them 14 dogs (36%) had 308 
ALT increase prior to LPP initiation. All dogs received at least 7 days of Denamarin®. ALT 309 
activity was monitored in 32 dogs during the LPP protocol. Twenty-eight dogs (87.5 %) had an 310 
ALT increase during the protocol but among these, only 19 dogs (59%) had an ALT increased 311 
>1.5 x baseline. VCOG grade III-IV ALT increase was documented in 10 dogs (31%). None of 312 
them had clinical signs of liver dysfunction. Among the 10 dogs with grade III-IV ALT 313 
increase, one had progressive disease and the other one received 2 lomustine administrations 314 
prior to LPP initiation.  The median number of LPP cycles prior to grade III-IV ALT increase 315 
was 2.5 (range 1-4 cycles). None of the analysed factors was significantly associated with grade 316 
III-IV ALT increase.  317 
 318 
Fourteen dogs (30%) had at a least one treatment delay due to neutropenia (n=9), 319 
gastrointestinal toxicity (3), fever/lethargy (1) and ALT increase (1). On univariable analysis, 320 
treatment delay was associated with weight (p<0.01), grade III-IV neutropenia (p<0.001), 321 
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lomustine dose in mg/kg (p=0.02), average daily procarbazine dose in mg/kg/day (p<0.1) and 322 
gastrointestinal toxicity (p<0.001). In multivariable analysis, only grade III-IV neutropenia 323 
(p<0.01, OR= 48.0, 95% CI 46.7-49.3) and gastrointestinal toxicity (p<0.01, OR = 14.43, 95% 324 
CI 13.45 – 15.41) were associated with treatment delay. Treatment delays consisted of 325 
discontinuation of procarbazine for several days until documentation of a normal neutrophil 326 
count or resolution of the clinical signs. In one dog, lomustine administration was delayed by 327 
one week following grade III ALT increase. ALT activity subsequently decreased and a new 328 
LPP cycle was initiated. Eight dogs (20%) had dose reduction following the identification of a 329 
grade IV neutropenia (n=7) or grade II gastrointestinal toxicity and lethargy (n=1). Dose 330 
reduction was performed if more than one LPP cycle was administered and consisted of a 10-331 
20% lomustine dose reduction according to clinician discretion and available tablet size.  332 
 333 
Discussion 334 
The primary goal of the study was to evaluate the use of LPP chemotherapy in dogs with 335 
relapsed multicentric lymphoma. A secondary goal was to identify predictive factors associated 336 
with response and toxicity.  337 
 338 
LPP was an effective rescue protocol with an overall response rate of 61% and a median TTD 339 
of 84 days for complete responders and 58 days for partial responders. This is consistent with 340 
previous studies using alkylating agent-based rescue protocols, which reported overall response 341 
rates ranging from 34%  to 65% and duration of response for responders from 63 days to 238 342 
days. 10–25  However, due to likely considerable differences in clinical management, geographic 343 
location and inclusion criteria, direct comparison with historical controls is not valid and only 344 
a large randomized prospective clinical trial could allow direct adequate comparison between 345 
various rescue protocols.35  346 
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 347 
When used as first line treatment for dogs with T-cell lymphoma, alkylating agent-based 348 
protocols such as LOPP and L-MOPP are associated with a high response rate (97-98%) and 349 
adequate progression-free survival (176 – 189 days).36,37 However, it is expected that response 350 
rate and duration decrease in a rescue setting. Therefore, it could be postulated that the number 351 
of previous relapses could be associated with response and TTD as was also proposed by Gillem 352 
and colleagues.17 In the present study, the number of previous relapses (p=0.98), protocols 353 
(p=0.82) and chemotherapy agents (p=0.92) were not associated with response nor with TTD. 354 
This may be due to small sample size and bias towards dogs with more resistant lymphomas. 355 
Indeed, for dogs treated with CHOP protocol as a first line treatment, Flory and colleagues 356 
demonstrated that the duration of time off chemotherapy prior to relapse was significantly 357 
associated with the likelihood of response to a second CHOP protocol.16 This suggested that 358 
most lymphomas in dogs that relapse shortly after protocol discontinuation or during 359 
chemotherapy are drug resistant and thus, may be less likely to respond to rescue protocols. All 360 
the dogs in the present study relapsed during a chemotherapy protocol and the time off 361 
chemotherapy was short (median = 14 days), supporting the hypothesis of a multi drug resistant 362 
phenotype.  363 
 364 
For TTD, the only significant factor on multivariable analysis was response and, not 365 
surprisingly, dogs with CR had a significantly longer TTD than dogs with PR, SD or PD. 366 
Interestingly, in univariable analysis, neutered females had a significantly (p=0.04) longer TTD 367 
compared to other sexes (42 days versus 19-23 days). Such finding was also reported by Fahey 368 
and colleagues; however, the lack of significance in multivariable analysis would suggests that 369 
“sex” may be a type I error. The use of L-asparaginase was also significantly associated with 370 
decreased TTD on univariable analysis (p=0.04). At our institution, L-asparaginase is mainly 371 
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administered to dogs with sub-stage b lymphoma, bone marrow and/or central nervous system 372 
involvement. Therefore, we could argue that those dogs that received L-asparaginase had a 373 
lymphoma with more aggressive biological behaviour and, possibly, less responsive to 374 
chemotherapy. Grade III/IV ALT increase was also associated with TTD on univariable 375 
analysis. In the present study, ALT increase occurred after a median of 2.5 cycles. Therefore, 376 
as suggested by Kristal and colleagues, ALT increase is likely to be due to lomustine cumulative 377 
toxicity.38 Consequently, the statistical association between TTD and VCOG grade III-IV ALT 378 
increase may be explained by cumulative lomustine toxicity and was not clinically relevant in 379 
this cohort.  380 
 381 
Although time to progression is recommended for the assessment of treatment response 382 
duration,39 TTD was considered a more objective index for this type of study. In a rescue setting, 383 
toxicity may be as important as tumour progression to justify protocol discontinuation. 384 
Additionally, progression was only assessed before starting a new cycle (every 21 days) and 385 
the time to progression could have been overestimated. The association between TTD and 386 
procarbazine dosing schedule (p=0.05) was unexpected. This may be a confounding effect as 387 
dogs receiving P-PCB had lower body weight compared to the C-PCB and received a higher 388 
average daily procarbazine (mg/kg/day) and lomustine dose (in mg/kg). Nonetheless, neither 389 
weight (p=0.1), procarbazine (in mg/kg/day, p=0.54) nor lomustine dose (in mg/kg, p=0.31) 390 
were associated with TTD on univariable analysis. This result could therefore suggest that, in 391 
a rescue setting, lymphoma could respond better to “pulsatile” procarbazine administration than 392 
to continuous administration. Further studies would be warranted to investigate the effect of 393 
this procarbazine dosing schedule on large breed dogs.  394 
 395 
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The achievement of CR on first-line chemotherapy protocol was significantly associated with 396 
response in univariable analysis. Similar findings were suggested by Fahey and colleagues, 397 
where dogs with relapsed lymphoma who responded to first-line protocol had a significantly 398 
longer TTD following UF-LOPP.15 Therefore, dogs that do not respond to first-line protocols 399 
may be inherently more resistant to chemotherapy through overexpression of P-gp, O6-400 
methylguanine-DNA methyltransferase (MGMT) or other mechanisms. Indeed, MGMT 401 
expression is associated with lomustine resistance in canine lymphoma cells and is also 402 
theoretically able to mediate procarbazine resistance.40–42 Studies investigating the relationship 403 
between MGMT activity status in canine lymphoma and response to LPP may be warranted. In 404 
humans with malignant astrocytoma, MGMT-methylation may be associated with increased 405 
response to PAV (procarbazine, nimustine, vincristine).43  406 
Interestingly, the average daily procarbazine dose, when expressed mg/kg/day, was 407 
significantly associated with response: dogs receiving higher procarbazine doses were more 408 
likely to achieve CR/PR. Dogs that had higher procarbazine doses had also more 409 
gastrointestinal adverse events and this may explain the significant association between 410 
gastrointestinal toxicity and response on univariable analysis. Not surprisingly, given the 411 
available procarbazine capsule size, smaller dogs received higher average daily procarbazine 412 
doses and were more likely to be included in the P-PCB dosing schedule. In addition, P-PCB 413 
regimen was significantly associated with TTD suggesting that pulsatile procarbazine dosing 414 
schedule may positively influence response. The higher response rate (77%) in the P-PCB group 415 
compared to C-PCB group (56%) may corroborate that.  416 
 417 
Several studies suggested that vincristine could be the major contributor of gastrointestinal 418 
toxicity observed with LOPP or MOPP protocol.15,19,24  As vincristine was not included in the 419 
LPP protocol, gastrointestinal toxicity would have been expected to be a less common finding; 420 
 18 
however, 29% of dogs had gastrointestinal toxicity and among them, 58% had grade I toxicity. 421 
This was similar to the toxicity reported for UF-LOPP (36%) or LOPP (>38.6%) but higher 422 
than for the combination of lomustine-dacarbazine (22%) or L-asparaginase, lomustine and 423 
prednisolone (21% vomiting, 10% diarrhoea) for dogs with relapsed lymphoma.10,15,19,25 This 424 
would suggest that vincristine may not be the main determinant for gastrointestinal toxicity. 425 
Other contributing factors or a more thorough owners’ report might also explain this result. 426 
Interestingly, the addition of vincristine to lomustine and procarbazine did not significantly 427 
increase the occurrence of gastrointestinal toxicity in a human study on oligodendroglial brain 428 
tumours.44 This may further support the minimal contribution of vincristine to the occurrence 429 
gastrointestinal adverse events when combined with procarbazine. In the present study, the 430 
average daily procarbazine dose (in mg/kg/day) was significantly associated with the 431 
occurrence of gastrointestinal toxicity and the weight of dogs with toxicity was significantly 432 
lower than those without gastrointestinal toxicity on univariable analysis (p=0.04, 19.45 kg vs 433 
29.4 kg). In addition, the weight was also associated with the occurrence of high-grade 434 
neutropenia. Taken together, these results highly suggested that smaller dogs might be relatively 435 
overdosed when using body surface area. Such a finding has been already established for 436 
doxorubicin, melphalan, and the combination of lomustine-cyclophosphamide.45–47 Therefore, 437 
as  with doxorubicin45 or as proposed by Saba and colleagues for lomustine, a different 438 
procarbazine dose for smaller dogs could be beneficial to decrease toxicity.25 However, this 439 
may affect response as higher procarbazine dose was associated with response to LPP in the 440 
present study.  441 
 442 
Similarly to other lomustine-based rescue protocols such as LOPP or lomustine single agent, 443 
neutropenia was relatively common with LPP (57%) and this reflects assessment of CBC at the 444 
time of the expected lomustine nadir and clinical relevance is unlikely.19,20 Indeed, only 33% 445 
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of dogs were reported to experience neutropenia (15% with high grade neutropenia) with the 446 
UF-LOPP protocol, 15 but CBC was not consistently performed at the suspected lomustine nadir 447 
and the occurrence of neutropenia was likely underestimated.15 In our study, in univariable 448 
analysis, dogs with pulsatile procarbazine dosing schedule were more likely to develop high-449 
grade neutropenia, suggesting pulse procarbazine was associated with increased 450 
myelosuppression. Pulsatile dosing was also associated with longer TTD and as high-grade 451 
neutropenia was asymptomatic in our population, the use of P-PCB may be more appropriate. 452 
This possible association between neutropenia and response duration has been previously 453 
shown for dogs with lymphoma treated with CHOP-based protocol.48  454 
 455 
The occurrence of thrombocytopenia was low (20%) in the present study. However, as it was 456 
documented in humans30 and suggested in dogs49, the long platelet lifespan may be responsible 457 
for a delayed thrombocytopenia occurrence that may occur weeks following the discontinuation 458 
of LPP protocol. Therefore, its incidence may have been underestimated.   459 
 460 
It is well recognized that lomustine can cause hepatocellular damage, resulting in serum ALT 461 
elevation in up to 86% of cancer-bearing dogs receiving therapeutic chemotherapy doses.38,50,51 462 
As Denamarin® was suggested to reduce ALT elevation in dogs treated with lomustine, all dogs 463 
in the present study received Denamarin® and ALT elevation was documented in 59% of the 464 
cases.52 Despite the use of Denamarin®, the occurrence of ALT elevation was consistent with 465 
previous studies investigating lomustine-based chemotherapy protocol with or without 466 
hepatoprotectant.15,19,50–52 However, as the studies are not directly comparable, the role of 467 
Denmarin® in the reduction of ALT elevation could not be assessed. There is no clear 468 
consensus to describe chemotherapy-induced ALT increase, and other factors (lymphoma 469 
infiltration, prednisolone treatment, underlying hepatopathy or procarbazine administration) 470 
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could participate to ALT serum activity.30,38 In the present study, grade III-IV ALT increase 471 
was responsible for LPP discontinuation in 4 dogs. Among them, 3 were in CR and one was in 472 
PR at the time of LPP discontinuation. Given the absence of associated clinical signs in these 473 
dogs and the possible reversible lomustine-induced ALT elevation, it is unknown whether 474 
chemotherapy delay could have been sufficient to reduce ALT while maintaining adequate 475 
response.50  476 
 477 
Although hospitalisation rate was consistent with previous studies, a 15% hospitalisation rate 478 
in a rescue setting can be considered relatively high. However, the recommendation for 479 
hospitalisation was at the clinician’s discretion, and may reflect owners’ concerns rather than 480 
the severity of clinical signs.15,19,24,37,48 According to the VCOG recommendations, 481 
hospitalisation is required only in case of grade III or higher adverse events. Therefore, 482 
hospitalisation would have been required only in two dogs (5%) with VCOG grade III 483 
gastrointestinal toxicity.32  The other four dogs presented VCOG grade I-II gastrointestinal 484 
toxicity and VCOG grade II lethargy.  485 
Limitations of this study are its retrospective nature and the small sample size. In addition, dogs 486 
were not consistently re-staged prior to LPP initiation and during the follow-up period, making 487 
the assessment of CR challenging: CR could have been overestimated as visceral non-target 488 
lesions were not consistently assessed in all patients.39 However, repeating complete clinical 489 
staging work-ups is rarely an option in dogs with relapsed lymphomas where owners face 490 
financial constraints and may try to minimise intervention due to the poor long-term prognosis. 491 
Classification of gastrointestinal toxicity was performed according to clinical records and the 492 
occurrence of gastrointestinal toxicity (especially VCOG grade 1) could have been 493 
underestimated; however, its clinical significance remains questionable. Although T-cell 494 
lymphoma has been suggested to be more responsive to alkylating-agent based chemotherapy 495 
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protocols, association with immunophenotype could not be analysed in our population, given 496 
the small number of dogs with T-cell lymphoma (n=6).36,37 Several studies showed that 497 
different lymphoma histological types had different prognosis and response to rescue protocol 498 
may follow a similar pattern.53–56 In the present study, histological classification was not 499 
consistently performed and the effect specific lymphoma histotype on response rate or TTD 500 
could not be investigated.  501 
 502 
In conclusion, these data support the use of LPP as a rescue protocol for dogs with lymphoma: 503 
the response rate was 61%, TTD for complete responders was 84 days and toxicity was 504 
acceptable. Our results also suggested that a more pulsatile procarbazine dosing schedule may 505 
improve treatment response. In addition, the use of oral chemotherapy alone should decrease 506 
hospital visit time, which may improve owner compliance and satisfaction in a rescue setting.  507 
 508 
 509 
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 684 
Tables and figure captions  685 
 686 
Table 1. Prednisone was administered orally at 30 mg/m2/day from day 1 to day 15, then 687 
reduced to 20mg/m2/day from day 15 to 21 and then maintained at 15mg/m2/day for the 688 
following cycles.  689 
 690 
Table 2. The use of L-asparaginase was considered only if performed within 14 days prior to 691 
LPP initiation. The C-PCB schedule includes dogs with daily procarbazine administration or 692 
with one day off a week and P-PCB dosing schedule includes dogs with every other day 693 
procarbazine administration or one day off every three days. The dog for which protocol was 694 
discontinued because of financial constraints or euthanasia due to non-lymphoma related causes 695 
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were censored from the TTD analysis. Only dogs for which the protocol was discontinued 696 
because of progressive disease was included in the analysis for TTP.  697 
 698 
Table 3. The highest toxicity grade is reported for each patient. For gastrointestinal events, 699 
the highest VCOG grade among vomiting, diarrhoea or anorexia was considered.    700 
 701 
Figure 1. Time from initiation to discontinuation for dogs who achieved CR (84 days range: 702 
23-167 days), PR (58 days, range: 19-75 days) and SD/PD (21 days, range: 19-22 days) 703 
treated with LPP (p<0.001). Time to progression for dogs achieving CR, PR and SD/PD was 704 
113 days (range 23-167 days), 58 days (range 19-75 days) and 21 days (range 19-22 days) 705 
respectively.   706 
